From the very start of the integration of IDS and Euroimmun activities, harmonizing and expanding the training programs for the IDS random access instruments was recognized as a strategic priority. This endeavor required extensive, open communication and close collaboration between the two organizations. Throughout the integration process, we successfully navigated several key challenges: Decentralized trainings:

In June 2026, Euroimmun received official confirmation from TÜV Rheinland LGA Products GmbH that all of its in vitro diagnostic devices currently on the market under Directive 98/79/EG (IVDD) may continue to be marketed in the European Union. This confirmation applies to all devices for which Euroimmun had submitted a corresponding application based on EU

Both experienced the journey of integrating IDS structures into Euroimmun firsthand: Anke Behne-Wachholz, Head of Customer Technical Operations, and Emma Storey, lead for the ChLIA Technical Services team, which consists of colleagues from both Euroimmun and IDS and is dedicated to supporting customers with questions and issues related to ChLIA automation. “Looking back on the

#bettertogether Last spring, IDS and Euroimmun launched the new random access instrument IDS i20. This new automation solution followed the random access instruments IDS-i10 and IDS-iSYS already established in the market. The device was developed based on IDS’ 50 years of expertise in laboratory automation – always focusing on maximum convenience for the users and reliability. For

Following the successful launch of our new design last summer, another change at Euroimmun and IDS takes place, which makes our affiliation to Revvity, Inc. more visible. As part of our strategic development, we are consolidating the technical systems of our three companies. This will enable us to provide an even better service thanks to